Replicate Bioscience News Today

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced acceptance of two oral presentations at the upcoming...

Researchers look ahead to the potential uses and benefits of a technology that has been more than 20 years in the making. Researchers look ahead to the potential uses and benefits of a technology that has been more than 20 years in the making.

/PRNewswire/ -- The "Global Lipid Nanoparticles Market Analysis & Forecast 2024-2034: Market By Type; By Application; By End-user; and By Region" report has...

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA) GlobeNewswire September 13, 2023 ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today...

The tech has lots of applications beyond the one we've already been injected with.

A variety of applications in development promise more potent and accurate attacks on a range of diseases.

Precision NanoSystems (PNI) will enter into a licensing agreement with Replicate Bioscience to develop self-replicating RNA (srRNA) therapies.

Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

Middle-East Arab News and Opinion - Asharq Al-Awsat is the world’s premier pan-Arab daily newspaper, printed simultaneously each day on four continents in 14 cities

Kiplinger’s annual roundup of economic good news, technological advances, and medical breakthroughs for you to celebrate on Thanksgiving and throughout the holiday season.